Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel Free BOLT Stock Alerts

Bolt Biotherapeutics (BOLT) Financials

Bolt Biotherapeutics logo
$5.93 +0.02 (+0.34%)
As of 11:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Bolt Biotherapeutics

Annual Income Statements for Bolt Biotherapeutics

This table shows Bolt Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -72 -99 -88 -69 -63 -33
Consolidated Net Income / (Loss)		 -61 -99 -88 -69 -63 -33
Net Income / (Loss) Continuing Operations		 -72 -99 -88 -69 -63 -33
Total Pre-Tax Income 		-72 -99 -88 -69 -63 -33
Total Operating Income		 -49 -93 -90 -76 -73 -36
Total Gross Profit		 0.23 1.26 5.73 7.88 7.69 7.70
Total Revenue		 0.23 1.26 5.73 7.88 7.69 7.70
Operating Revenue		 0.23 1.26 - 7.88 7.69 7.70
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 49 94 96 84 81 44
Selling, General & Admin Expense		 9.06 18 23 23 18 14
Research & Development Expense		 40 76 73 62 57 29
Impairment Charge		 - - - 0.00 1.47 0.00
Restructuring Charge		 - - - 0.00 3.34 1.48
Total Other Income / (Expense), net		 -23 -5.80 2.22 7.00 9.93 2.74
Interest & Investment Income		 0.20 0.28 2.22 7.00 5.26 2.50
Other Income / (Expense), net		 -23 -6.08 - 0.00 4.68 0.24
Basic Earnings per Share		 ($28.89) ($2.97) ($2.36) ($1.83) ($33.06) ($17.85)
Weighted Average Basic Shares Outstanding		 2.10M 33.20M 37.36M 37.81M 1.91M 1.87M
Diluted Earnings per Share		 ($28.89) ($2.97) ($2.36) ($1.83) ($33.06) ($17.85)
Weighted Average Diluted Shares Outstanding		 2.10M 33.20M 37.36M 37.81M 1.91M 1.87M
Weighted Average Basic & Diluted Shares Outstanding		 2.10M 33.20M 37.81M 38.13M 38.34M 1.92M

Quarterly Income Statements for Bolt Biotherapeutics

This table shows Bolt Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.42
Consolidated Net Income / (Loss)		 -11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.42
Net Income / (Loss) Continuing Operations		 -11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.42
Total Pre-Tax Income 		-11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.42
Total Operating Income		 -17 -23 -16 -17 -12 -9.21 -7.70 -7.09 -7.60 -8.37 -4.73
Total Gross Profit		 5.27 1.28 1.14 - 1.22 1.80 2.17 2.50 0.03 0.01 0.00
Total Revenue		 5.27 1.28 1.14 - 1.22 1.80 2.17 2.50 0.03 0.01 0.00
Operating Revenue		 5.27 1.28 1.14 - 1.22 1.80 2.17 2.50 0.03 0.01 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 22 24 18 17 13 11 9.87 9.59 7.63 8.38 4.73
Selling, General & Admin Expense		 5.84 4.87 3.80 3.95 3.83 3.52 3.34 3.12 2.80 2.42 2.52
Research & Development Expense		 17 15 14 12 9.51 7.50 6.54 4.99 4.83 5.15 2.21
Impairment Charge		 - - - - - 0.00 0.00 - - 0.81 0.00
Total Other Income / (Expense), net		 6.28 1.40 1.27 0.98 1.08 0.65 0.56 0.45 0.36 0.65 0.31
Interest & Investment Income		 1.61 1.40 1.27 0.98 1.05 0.60 0.48 0.37 0.28 0.18 0.15
Other Income / (Expense), net		 4.68 0.00 0.00 - 0.02 0.05 0.08 0.09 0.08 0.48 0.16
Basic Earnings per Share		 ($0.28) ($11.12) ($7.93) ($8.35) ($5.76) ($4.46) ($3.72) ($3.55) ($4.31) ($4.57) ($2.25)
Weighted Average Basic Shares Outstanding		 38.07M 1.91M 1.91M 1.91M 1.92M 1.92M 1.92M 1.87M 1.68M 1.69M 1.97M
Diluted Earnings per Share		 ($0.28) ($11.12) ($7.93) ($8.35) ($5.76) ($4.46) ($3.72) ($3.55) ($4.31) ($4.57) ($2.25)
Weighted Average Diluted Shares Outstanding		 38.07M 1.91M 1.91M 1.91M 1.92M 1.92M 1.92M 1.87M 1.68M 1.69M 1.97M
Weighted Average Basic & Diluted Shares Outstanding		 38.13M 38.26M 38.27M 38.34M 38.34M 1.92M 1.92M 1.92M 1.92M 1.93M 2.61M

Annual Cash Flow Statements for Bolt Biotherapeutics

This table details how cash moves in and out of Bolt Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -28 22 -18 1.77 -3.61 4.47
Net Cash From Operating Activities		 -47 -57 -77 -70 -61 -40
Net Cash From Continuing Operating Activities		 -47 -57 -77 -70 -61 -40
Net Income / (Loss) Continuing Operations		 -61 -99 -88 -69 -63 -33
Consolidated Net Income / (Loss)		 -61 -99 -88 -69 -63 -33
Depreciation Expense		 0.61 1.19 1.67 1.85 1.78 1.29
Amortization Expense		 0.03 2.65 0.18 -1.54 -2.62 -0.67
Non-Cash Adjustments To Reconcile Net Income		 15 17 13 9.22 9.69 5.02
Changes in Operating Assets and Liabilities, net		 -2.28 21 -3.06 -9.86 -7.03 -12
Net Cash From Investing Activities		 -21 -232 58 71 58 44
Net Cash From Continuing Investing Activities		 -21 -232 58 71 58 44
Purchase of Property, Plant & Equipment		 -3.26 -2.34 -1.95 -0.21 -0.04 -0.07
Purchase of Investments		 -33 -313 -181 -165 -89 -29
Sale of Property, Plant & Equipment		 - - - 0.00 0.15 0.96
Sale and/or Maturity of Investments		 16 84 241 236 146 72
Net Cash From Financing Activities		 40 311 0.50 0.25 0.11 0.02
Net Cash From Continuing Financing Activities		 40 311 0.50 0.25 0.11 0.02
Issuance of Common Equity		 0.29 259 0.50 0.25 0.11 0.02

Quarterly Cash Flow Statements for Bolt Biotherapeutics

This table details how cash moves in and out of Bolt Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -6.55 1.94 3.17 -2.17 1.19 1.21 8.15 -6.08 -0.09 1.25 0.92
Net Cash From Operating Activities		 -17 -16 -14 -14 -13 -9.60 -9.73 -7.16 -8.02 -6.54 -3.08
Net Cash From Continuing Operating Activities		 -17 -16 -14 -14 -13 -9.60 -9.73 -7.16 -8.02 -6.54 -3.08
Net Income / (Loss) Continuing Operations		 -11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.59
Consolidated Net Income / (Loss)		 -11 -21 -15 -16 -11 -8.56 -7.14 -6.63 -7.24 -7.72 -4.59
Depreciation Expense		 0.46 0.46 0.44 0.43 0.40 0.35 0.29 0.26 0.20 0.17 0.07
Amortization Expense		 -1.03 -0.79 -0.48 -0.31 -0.21 -0.17 -0.13 -0.16 -0.05 -0.08 -0.01
Non-Cash Adjustments To Reconcile Net Income		 3.08 3.61 1.83 1.17 1.04 1.25 1.04 1.69 1.18 1.67 1.37
Changes in Operating Assets and Liabilities, net		 -8.44 1.77 -0.58 0.22 -3.55 -2.46 -3.79 -2.31 -2.12 -0.58 0.08
Net Cash From Investing Activities		 10 18 17 12 15 11 18 1.07 7.92 7.77 4.00
Net Cash From Continuing Investing Activities		 10 18 17 12 15 11 18 1.07 7.92 7.77 4.00
Sale of Property, Plant & Equipment		 0.00 - 0.15 - 0.96 - - - 0.03 0.69 0.01
Sale and/or Maturity of Investments		 33 50 37 25 15 25 20 13 9.12 7.10 4.00

Annual Balance Sheets for Bolt Biotherapeutics

This table presents Bolt Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 47 308 228 160 100 57
Total Current Assets		 25 189 173 106 51 30
Cash & Equivalents		 5.54 27 9.24 11 7.21 12
Restricted Cash		 - - - 0.00 0.78 0.20
Short-Term Investments		 17 159 160 91 40 16
Prepaid Expenses		 2.52 2.94 3.86 3.52 2.71 2.56
Plant, Property, & Equipment, net		 4.08 6.16 6.45 4.96 3.14 1.25
Total Noncurrent Assets		 17 112 49 49 46 25
Long-Term Investments		 0.00 85 24 26 23 4.34
Other Noncurrent Operating Assets		 17 27 25 23 23 21
Total Liabilities & Shareholders' Equity		 47 308 228 160 100 57
Total Liabilities		 46 58 56 47 42 30
Total Current Liabilities		 11 21 23 20 16 8.44
Accounts Payable		 1.60 3.57 3.59 2.99 1.51 1.44
Accrued Expenses		 6.66 12 15 12 9.08 3.72
Current Deferred Revenue		 1.50 2.87 1.99 2.20 3.02 0.45
Other Current Liabilities		 1.50 2.50 2.39 2.78 2.25 2.83
Total Noncurrent Liabilities		 35 36 33 27 27 22
Noncurrent Deferred Revenue		 0.00 14 13 9.11 3.62 1.54
Other Noncurrent Operating Liabilities		 35 22 20 17 23 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -105 250 172 113 57 27
Total Preferred & Common Equity		 -105 250 172 113 57 27
Total Common Equity		 -105 250 172 113 57 27
Common Stock		 3.45 457 468 477 485 487
Retained Earnings		 -108 -207 -295 -364 -427 -461
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.32 -0.92 0.04 0.10 -0.02

Quarterly Balance Sheets for Bolt Biotherapeutics

This table presents Bolt Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 143 124 109 86 75 65 48 40 36
Total Current Assets		 95 77 57 43 38 36 26 21 17
Cash & Equivalents		 4.26 6.20 9.37 8.39 9.60 18 12 13 14
Restricted Cash		 - - 0.79 0.78 0.78 0.78 0.20 0.20 0.20
Short-Term Investments		 87 67 44 30 25 14 11 4.74 1.02
Prepaid Expenses		 3.71 2.93 2.56 2.89 2.78 2.91 2.66 2.77 2.08
Plant, Property, & Equipment, net		 4.50 4.08 3.57 2.07 1.72 1.50 1.04 0.57 0.34
Total Noncurrent Assets		 43 43 49 41 35 28 21 19 18
Long-Term Investments		 21 24 31 19 14 6.91 1.02 0.51 0.25
Other Noncurrent Operating Assets		 22 20 18 22 22 21 20 19 18
Total Liabilities & Shareholders' Equity		 143 124 109 86 75 65 48 40 36
Total Liabilities		 39 38 37 39 37 33 28 28 27
Total Current Liabilities		 17 18 18 14 12 9.97 7.34 7.87 8.32
Accounts Payable		 2.22 2.63 1.48 1.53 1.85 1.52 1.74 0.87 0.63
Accrued Expenses		 9.71 10 12 6.55 5.39 3.84 2.02 3.09 3.39
Current Deferred Revenue		 1.91 2.02 1.97 3.08 2.51 1.91 0.63 0.82 1.07
Other Current Liabilities		 2.89 3.00 2.82 2.40 2.56 2.70 2.96 3.09 3.23
Total Noncurrent Liabilities		 22 20 19 25 24 23 21 20 19
Noncurrent Deferred Revenue		 5.33 4.52 3.87 3.05 2.59 1.96 1.35 1.17 0.92
Other Noncurrent Operating Liabilities		 17 16 15 22 22 21 20 19 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 104 86 72 47 39 32 20 13 8.56
Total Preferred & Common Equity		 104 86 72 47 39 32 20 13 8.56
Total Common Equity		 104 86 72 47 39 32 20 13 8.56
Common Stock		 479 482 483 485 486 486 488 488 489
Retained Earnings		 -375 -396 -411 -438 -447 -454 -468 -476 -480
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.04 0.21 0.04 -0.01 -0.01 -0.01 -0.04 -0.04

Annual Metrics And Ratios for Bolt Biotherapeutics

This table displays calculated financial ratios and metrics derived from Bolt Biotherapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 37,284,650.00 37,660,893.00 37,965,870.00 38,273,002.00 1,919,441.00
DEI Adjusted Shares Outstanding		 0.00 1,864,233.00 1,883,045.00 1,898,294.00 1,913,650.00 1,919,441.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -53.06 -46.78 -36.45 -32.98 -17.39
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 445.45% 354.68% 37.48% -2.36% 0.07%
EBITDA Growth		 0.00% -32.30% 6.90% 14.23% 8.80% 49.06%
EBIT Growth		 0.00% -36.43% 8.65% 15.64% 10.27% 47.53%
NOPAT Growth		 0.00% -88.66% 2.66% 15.64% 4.13% 50.56%
Net Income Growth		 0.00% -62.35% 10.64% 21.45% 8.79% 47.12%
EPS Growth		 0.00% 89.72% 20.54% 22.46% 8.79% 46.01%
Operating Cash Flow Growth		 0.00% -20.63% -34.06% 9.12% 11.85% 34.98%
Free Cash Flow Firm Growth		 0.00% 0.00% 4.01% 7.18% 9.52% 36.98%
Invested Capital Growth		 0.00% 4.63% 0.57% 25.62% 13.06% 59.84%
Revenue Q/Q Growth		 0.00% 67.55% 18.71% 9.42% -21.36% 48.12%
EBITDA Q/Q Growth		 0.00% 14.74% 5.19% 4.42% 1.06% 21.92%
EBIT Q/Q Growth		 0.00% 13.57% 6.26% 1.64% 4.00% 21.66%
NOPAT Q/Q Growth		 0.00% -12.29% 6.26% 1.64% 3.76% 21.40%
Net Income Q/Q Growth		 0.00% 3.78% 7.52% 2.94% 3.02% 21.80%
EPS Q/Q Growth		 0.00% 82.65% 1.26% 3.17% 3.02% 19.74%
Operating Cash Flow Q/Q Growth		 0.00% -9.40% -0.21% 5.04% -0.27% 15.44%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -2.25% 5.53% -0.25% 11.34%
Invested Capital Q/Q Growth		 0.00% -37.32% -0.99% -21.05% -4.80% 26.16%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -31,094.37% -7,541.67% -1,544.27% -963.47% -899.96% -458.10%
Operating Margin		 -21,290.91% -7,364.13% -1,576.56% -967.45% -949.91% -469.30%
EBIT Margin		 -31,373.59% -7,846.98% -1,576.56% -967.45% -889.12% -466.17%
Profit (Net Income) Margin		 -26,289.18% -7,824.68% -1,537.76% -878.58% -820.78% -433.74%
Tax Burden Percent		 84.02% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.73% 99.72% 97.54% 90.81% 92.31% 93.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17,400.57% -78.73% -41.79% -48.69% -74.28% -79.75%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -155.72% -55.82% -33.73% -39.32% -52.71% -45.88%
Return on Assets (ROA)		 -130.48% -55.66% -32.90% -35.71% -48.66% -42.69%
Return on Common Equity (ROCE)		 5,232,486.94% -45.63% -41.79% -48.69% -74.28% -79.75%
Return on Equity Simple (ROE_SIMPLE)		 57.87% -39.42% -51.37% -61.38% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -34 -65 -63 -53 -51 -25
NOPAT Margin		 -14,903.64% -5,154.89% -1,103.59% -677.21% -664.94% -328.51%
Net Nonoperating Expense Percent (NNEP)		 -115.16% -22.85% -10.71% -9.87% -12.01% -15.72%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.31% -89.40% -95.37%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 3,920.35% 1,459.76% 400.19% 286.06% 240.01% 179.27%
R&D to Revenue		 17,470.56% 6,004.37% 1,276.37% 781.39% 747.32% 370.80%
Operating Expenses to Revenue		 21,390.91% 7,464.13% 1,676.56% 1,067.45% 1,049.91% 569.30%
Earnings before Interest and Taxes (EBIT)		 -72 -99 -90 -76 -68 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -72 -95 -88 -76 -69 -35
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.73 0.29 0.38 0.36 0.40
Price to Tangible Book Value (P/TBV)		 0.00 0.73 0.29 0.38 0.36 0.40
Price to Revenue (P/Rev)		 995.67 145.00 8.55 5.40 2.66 1.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,352.63 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -65.44 -1.18 -1.10 -1.13 -1.17 -1.23
Leverage Ratio		 133.36 1.41 1.27 1.36 1.53 1.87
Compound Leverage Factor		 132.99 1.41 1.24 1.24 1.41 1.74
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 30,170.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -30,070.77% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -5.04 0.56 -1.79 -3.53 -7.48 -12.65
Noncontrolling Interest Sharing Ratio		 30,170.77% 42.04% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 2.25 8.87 7.47 5.17 3.20 3.59
Quick Ratio		 2.03 8.73 7.31 5.00 2.98 3.26
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -66 -63 -59 -53 -34
Operating Cash Flow to CapEx		 -1,450.28% -2,440.80% -3,917.26% -33,750.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.04 0.06 0.10
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.06 0.25 0.91 1.38 1.90 3.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -22 -21 -21 -16 -14 -5.54
Invested Capital Turnover		 -0.01 -0.06 -0.27 -0.42 -0.52 -0.80
Increase / (Decrease) in Invested Capital		 0.00 1.04 0.12 5.46 2.07 8.25
Enterprise Value (EV)		 312 -89 -144 -86 -51 -22
Market Capitalization		 230 183 49 43 20 10
Book Value per Share		 ($49.92) $6.71 $4.55 $2.97 $1.49 $13.81
Tangible Book Value per Share		 ($49.92) $6.71 $4.55 $2.97 $1.49 $13.81
Total Capital		 0.35 250 172 113 57 27
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -23 -272 -193 -129 -71 -32
Capital Expenditures (CapEx)		 3.26 2.34 1.95 0.21 -0.11 -0.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.74 -18 -19 -17 -13 -5.88
Debt-free Net Working Capital (DFNWC)		 14 168 150 85 35 22
Net Working Capital (NWC)		 14 168 150 85 35 22
Net Nonoperating Expense (NNE)		 26 34 25 16 12 8.10
Net Nonoperating Obligations (NNO)		 -23 -272 -193 -129 -71 -32
Total Depreciation and Amortization (D&A)		 0.65 3.85 1.85 0.31 -0.83 0.62
Debt-free, Cash-free Net Working Capital to Revenue		 -3,783.98% -1,459.29% -336.18% -215.05% -170.99% -76.41%
Debt-free Net Working Capital to Revenue		 6,102.60% 13,320.00% 2,611.76% 1,082.43% 454.59% 283.63%
Net Working Capital to Revenue		 6,102.60% 13,320.00% 2,611.76% 1,082.43% 454.59% 283.63%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.97) ($2.36) ($1.83) ($33.00) ($17.85)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.47M 37.36M 37.81M 1.91M 1.87M
Adjusted Diluted Earnings per Share		 $0.00 ($2.97) ($2.36) ($1.83) ($33.00) ($17.85)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.47M 37.36M 37.81M 1.91M 1.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.97) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 33.20M 37.81M 38.13M 1.92M 1.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -65 -63 -53 -48 -24
Normalized NOPAT Margin		 -14,903.64% -5,154.89% -1,103.59% -677.21% -621.13% -315.05%
Pre Tax Income Margin		 -31,287.45% -7,824.68% -1,537.76% -878.58% -820.78% -433.74%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Bolt Biotherapeutics

This table displays calculated financial ratios and metrics derived from Bolt Biotherapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 38,127,740.00 38,127,740.00 38,264,843.00 38,273,002.00 38,339,697.00 38,339,697.00 1,919,441.00 1,919,441.00 1,921,567.00 1,921,567.00 1,926,345.00
DEI Adjusted Shares Outstanding		 1,906,387.00 1,906,387.00 1,913,242.00 1,913,650.00 1,916,985.00 1,916,985.00 1,919,441.00 1,919,441.00 1,921,567.00 1,921,567.00 1,926,345.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.67 -11.12 -7.93 -8.33 -5.76 -4.47 -3.72 -3.45 -3.77 -4.02 -2.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 188.83% -11.03% -54.87% 0.00% -76.83% 41.49% 90.10% 0.00% -97.87% -99.72% -100.00%
EBITDA Growth		 30.89% -11.94% 13.49% 4.24% 8.38% 60.83% 54.74% 58.90% 38.15% 13.12% 39.54%
EBIT Growth		 32.57% -13.94% 9.57% 14.42% 2.61% 59.46% 53.65% 58.63% 37.82% 13.78% 40.07%
NOPAT Growth		 7.18% -13.94% 9.57% 14.42% 29.12% 59.24% 53.15% 58.12% 37.26% 9.08% 38.60%
Net Income Growth		 36.33% -17.38% 6.65% 10.99% -2.12% 59.61% 52.93% 58.39% 34.38% 9.82% 38.10%
EPS Growth		 37.78% -17.38% 6.65% 10.99% -2.12% 59.89% 53.09% 57.49% 25.17% -2.47% 39.52%
Operating Cash Flow Growth		 28.41% -6.82% 16.62% -1.16% 20.21% 40.55% 30.32% 50.41% 39.97% 31.85% 68.37%
Free Cash Flow Firm Growth		 -0.97% -31.04% 44.77% 27.91% 68.63% 59.78% 3.54% 5.04% -148.94% -38.39% 62.65%
Invested Capital Growth		 34.84% 21.95% -0.41% 13.06% -37.85% 10.58% 43.00% 59.84% 64.04% 45.70% 10.88%
Revenue Q/Q Growth		 152.47% -75.82% -10.51% 0.00% 0.00% 47.63% 20.23% 15.26% -98.96% -80.77% -100.00%
EBITDA Q/Q Growth		 25.93% -76.50% 28.11% -1.89% 29.14% 24.53% 16.94% 7.47% -6.63% -6.00% 42.20%
EBIT Q/Q Growth		 37.18% -81.98% 27.23% -2.88% 28.51% 24.25% 16.80% 8.17% -7.46% -5.03% 42.18%
NOPAT Q/Q Growth		 13.53% -32.21% 27.23% -2.88% 28.38% 23.98% 16.36% 8.02% -7.28% -10.17% 43.52%
Net Income Q/Q Growth		 39.61% -96.05% 28.40% -5.01% 30.72% 22.45% 16.55% 7.18% -9.24% -6.57% 42.72%
EPS Q/Q Growth		 40.43% -96.05% 28.40% -5.01% 30.72% 22.57% 16.59% 4.57% -21.41% -6.03% 50.77%
Operating Cash Flow Q/Q Growth		 -17.43% 3.64% 13.48% -3.32% 7.38% 28.19% -1.41% 26.47% -12.12% 18.48% 52.94%
Free Cash Flow Firm Q/Q Growth		 14.04% -15.13% 40.02% -21.45% 62.59% -47.57% -43.84% -19.56% 1.91% 17.96% 61.18%
Invested Capital Q/Q Growth		 45.45% -34.89% -12.73% -4.80% 13.50% 12.50% 28.14% 26.16% 22.54% -32.13% -17.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -246.34% -1,798.51% -1,444.87% 0.00% -974.06% -497.95% -343.98% -276.16% -28,315.38% -156,080.00% 0.00%
Operating Margin		 -324.08% -1,772.31% -1,441.10% 0.00% -991.41% -510.53% -355.14% -283.40% -29,234.62% -167,480.00% 0.00%
EBIT Margin		 -235.44% -1,772.31% -1,441.10% 0.00% -989.61% -507.76% -351.36% -279.92% -28,923.08% -157,960.00% 0.00%
Profit (Net Income) Margin		 -204.99% -1,662.35% -1,330.06% 0.00% -903.44% -474.56% -329.37% -265.24% -27,861.54% -154,400.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 87.07% 93.80% 92.29% 94.21% 91.29% 93.46% 93.74% 94.76% 96.33% 97.75% 96.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -48.14% -58.04% -64.99% -74.28% -83.92% -81.33% -81.97% -79.75% -88.79% -111.65% -127.96%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -15.28% -125.70% -99.00% 0.00% -31.48% -21.19% -20.93% -27.55% -2,807.86% -12,817.55% 0.00%
Return on Assets (ROA)		 -13.30% -117.90% -91.37% 0.00% -28.74% -19.81% -19.62% -26.10% -2,704.81% -12,528.68% 0.00%
Return on Common Equity (ROCE)		 -48.14% -58.04% -64.99% -74.28% -83.92% -81.33% -81.97% -79.75% -88.79% -111.65% -127.96%
Return on Equity Simple (ROE_SIMPLE)		 -60.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -16 -12 -12 -8.48 -6.45 -5.39 -4.96 -5.32 -5.86 -3.31
NOPAT Margin		 -226.86% -1,240.62% -1,008.77% 0.00% -693.99% -357.37% -248.60% -198.38% -20,464.23% -117,236.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.81% -4.22% -3.24% -4.10% -2.98% -2.88% -2.81% -3.24% -4.64% -5.50% -4.05%
Return On Investment Capital (ROIC_SIMPLE)		 -11.49% -18.42% -15.98% -20.70% -18.12% -16.60% -16.80% -18.71% -26.84% -46.38% -38.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 110.68% 382.27% 332.95% 0.00% 313.01% 194.90% 153.85% 124.68% 10,761.54% 48,440.00% 0.00%
R&D to Revenue		 313.41% 1,210.43% 1,208.15% 0.00% 778.40% 415.63% 301.29% 199.52% 18,573.08% 102,980.00% 0.00%
Operating Expenses to Revenue		 424.08% 1,872.31% 1,541.10% 0.00% 1,091.41% 610.53% 455.14% 383.40% 29,334.62% 167,580.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -12 -23 -16 -17 -12 -9.16 -7.62 -7.00 -7.52 -7.90 -4.57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -23 -16 -17 -12 -8.98 -7.46 -6.90 -7.36 -7.80 -4.51
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.51 0.33 0.34 0.36 0.33 0.28 0.32 0.40 0.39 0.59 0.83
Price to Tangible Book Value (P/TBV)		 0.51 0.33 0.34 0.36 0.33 0.28 0.32 0.40 0.39 0.59 0.83
Price to Revenue (P/Rev)		 4.71 2.56 2.54 2.66 4.22 2.65 1.97 1.36 1.19 1.57 2.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.12 -1.13 -1.17 -1.14 -1.18 -1.20 -1.23 -1.24 -1.31 -1.35
Leverage Ratio		 1.33 1.38 1.42 1.53 1.52 1.60 1.67 1.87 2.01 2.25 2.48
Compound Leverage Factor		 1.16 1.30 1.31 1.44 1.38 1.50 1.57 1.77 1.94 2.20 2.40
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.40 -3.96 -4.85 -5.78 -6.93 -8.04 -9.42 -10.97 -13.40 -16.50 -18.79
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.68 4.28 3.16 3.20 3.13 3.11 3.57 3.59 3.51 2.61 2.05
Quick Ratio		 5.46 4.12 2.98 2.98 2.86 2.82 3.20 3.26 3.12 2.24 1.78
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -19 -11 -14 -5.21 -7.68 -11 -13 -13 -11 -4.13
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.07 0.07 0.06 0.03 0.04 0.06 0.10 0.10 0.08 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.15 2.31 2.21 1.90 1.11 1.44 2.05 3.51 4.18 4.11 2.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.65 -12 -13 -14 -12 -10 -7.50 -5.54 -4.29 -5.67 -6.68
Invested Capital Turnover		 -1.03 -0.84 -0.74 -0.52 -0.35 -0.38 -0.50 -0.80 -0.80 -0.58 -0.36
Increase / (Decrease) in Invested Capital		 4.63 3.28 -0.05 2.07 -3.28 1.24 5.66 8.25 7.64 4.77 0.82
Enterprise Value (EV)		 -59 -69 -60 -51 -43 -38 -29 -22 -16 -11 -8.16
Market Capitalization		 53 29 25 20 15 11 10 10 7.76 7.40 7.09
Book Value per Share		 $2.73 $2.25 $1.88 $1.49 $1.22 $1.01 $16.72 $13.81 $10.32 $6.58 $4.44
Tangible Book Value per Share		 $2.73 $2.25 $1.88 $1.49 $1.22 $1.01 $16.72 $13.81 $10.32 $6.58 $4.44
Total Capital		 104 86 72 57 47 39 32 27 20 13 8.56
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -113 -98 -85 -71 -59 -49 -40 -32 -24 -18 -15
Capital Expenditures (CapEx)		 0.00 0.00 -0.15 0.00 -0.96 0.00 0.00 0.00 -0.03 -0.67 -0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -15 -16 -13 -11 -9.53 -7.05 -5.88 -4.68 -5.10 -6.23
Debt-free Net Working Capital (DFNWC)		 78 59 39 35 29 26 26 22 18 13 8.77
Net Working Capital (NWC)		 78 59 39 35 29 26 26 22 18 13 8.77
Net Nonoperating Expense (NNE)		 -1.15 5.38 3.67 4.09 2.56 2.11 1.75 1.67 1.92 1.86 1.11
Net Nonoperating Obligations (NNO)		 -113 -98 -85 -71 -59 -49 -40 -32 -24 -18 -15
Total Depreciation and Amortization (D&A)		 -0.58 -0.33 -0.04 0.12 0.19 0.18 0.16 0.09 0.16 0.09 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 -114.96% -134.03% -158.77% -170.99% -293.43% -228.63% -135.78% -76.41% -72.06% -108.53% -246.27%
Debt-free Net Working Capital to Revenue		 691.73% 525.98% 399.47% 454.59% 795.68% 624.57% 493.55% 283.63% 283.26% 270.15% 346.31%
Net Working Capital to Revenue		 691.73% 525.98% 399.47% 454.59% 795.68% 624.57% 493.55% 283.63% 283.26% 270.15% 346.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.28) ($11.20) ($8.00) ($167.00) ($5.80) ($4.46) ($3.72) ($3.55) ($4.31) ($4.57) ($2.25)
Adjusted Weighted Average Basic Shares Outstanding		 38.07M 1.91M 1.91M 95.46K 1.92M 1.92M 1.92M 1.87M 1.68M 1.69M 1.97M
Adjusted Diluted Earnings per Share		 ($0.28) ($11.20) ($8.00) ($167.00) ($5.80) ($4.46) ($3.72) ($3.55) ($4.31) ($4.57) ($2.25)
Adjusted Weighted Average Diluted Shares Outstanding		 38.07M 1.91M 1.91M 95.46K 1.92M 1.92M 1.92M 1.87M 1.68M 1.69M 1.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($167.00) $0.00 $0.00 $0.00 ($3.55) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.13M 1.91M 1.91M 1.92M 1.92M 1.92M 1.92M 1.92M 1.92M 1.93M 2.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -13 -12 -12 -8.48 -6.45 -5.39 -4.96 -5.32 -5.30 -3.31
Normalized NOPAT Margin		 -226.86% -1,044.89% -1,008.77% 0.00% -693.99% -357.37% -248.60% -198.38% -20,464.23% -105,924.00% 0.00%
Pre Tax Income Margin		 -204.99% -1,662.35% -1,330.06% 0.00% -903.44% -474.56% -329.37% -265.24% -27,861.54% -154,400.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Bolt Biotherapeutics’ financial statements show lower operating expenses and a slowing cash burn, but the company remains deeply unprofitable with minimal revenue and a shrinking liquidity position. The latest quarter, Q2 2026, reported a net loss of $7.7 million, compared with losses of $7.2 million in Q1 2026 and $6.6 million in Q4 2025.

  • Operating cash burn has improved. Net cash used in operating activities declined from $16.8 million in Q1 2024 and $16.1 million in Q2 2024 to $6.5 million in Q2 2026. The latest figure was also better than the $8.0 million used in Q1 2026.
  • Operating expenses are substantially lower than in 2024. Q2 2026 operating expenses were $8.4 million, including $5.1 million of research and development spending and $2.4 million of selling, general and administrative expenses. This compares with $22.4 million of operating expenses in Q1 2024 and $23.9 million in Q2 2024.
  • Liquidity remains adequate in the near term. At June 30, 2026, Bolt reported $12.9 million of cash, $4.7 million of short-term investments, $0.5 million of long-term investments and $0.2 million of restricted cash. Total current assets of $20.6 million exceeded current liabilities of $7.9 million.
  • Q2 cash increased by $1.3 million. Investing activity generated $7.8 million, primarily because of $7.1 million in investment maturities or sales and $0.7 million from the sale of property and equipment. This offset the $6.5 million operating cash outflow.
  • Revenue remains inconsistent and largely dependent on collaboration activity. Revenue was $5,000 in Q2 2026, down from $26,000 in Q1 2026 and far below the $1.8 million reported in Q2 2025 and $5.3 million in Q1 2024. The statements do not show a recurring commercial revenue base.
  • The company has limited debt exposure. Bolt’s statements list no significant interest-bearing debt, which reduces direct financing pressure. However, total liabilities were still $27.7 million, including $18.7 million of other noncurrent operating liabilities.
  • Operating losses continue despite cost reductions. Bolt recorded an operating loss of $8.4 million in Q2 2026, while interest and other income of $0.7 million only partially reduced the net loss to $7.7 million. The company has reported a net loss in every quarter provided.
  • Cash and investment balances have declined sharply over the longer period. Cash, restricted cash and investments totaled approximately $18.3 million at the end of Q2 2026, compared with approximately $43.7 million in Q2 2025 and $92.7 million in Q1 2024. Continued operating losses could require additional financing or further asset sales.
  • Q2’s positive cash movement was not generated by the business. The increase in cash was driven primarily by selling or maturing investments and selling property and equipment, rather than operating revenue or positive operating cash flow.
  • Shareholder equity has deteriorated. Total equity fell to $12.6 million at June 30, 2026, from $19.8 million at March 31, 2026, $32.1 million at September 30, 2025, and $85.9 million at June 30, 2024. Retained earnings were negative $475.7 million, reflecting the company’s cumulative losses.

Overall, the financial trend is mixed. Bolt has reduced spending and narrowed its quarterly operating cash burn, which may extend its runway. However, revenue has collapsed to negligible levels, losses remain substantial and available cash and investments have contracted considerably. Investors should focus on whether Bolt can produce meaningful recurring revenue or secure additional funding before its current liquidity is exhausted.

11/13/26 10:18 AM ETAI Generated. May Contain Errors.

Bolt Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bolt Biotherapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bolt Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$33.38 million in 2025, rising from -$60.73 million in 2020. The previous period was -$63.12 million in 2024. See Bolt Biotherapeutics' forecast for analyst expectations on what's next for the company.

Bolt Biotherapeutics' total operating income in 2025 was -$36.11 million, based on the following breakdown:
  • Total Gross Profit: $7.70 million
  • Total Operating Expenses: $43.81 million

Over the last 5 years, Bolt Biotherapeutics' total revenue changed from $231 thousand in 2020 to $7.70 million in 2025, a change of 3,231.2%.

In the past 10 quarters, Bolt Biotherapeutics' cash and equivalents has ranged from $4.26 million in Q1 2024 to $17.75 million in Q3 2025, and is currently $13.78 million as of their latest financial filing in Q3 2026.

Bolt Biotherapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, Bolt Biotherapeutics' book value per share changed from -49.92 in 2020 to 13.81 in 2025.


Related Companies

Financial statements for NASDAQ:BOLT last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel